Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023 Feb 7, 2023
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office Jan 24, 2023
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results Jan 6, 2023
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference Jan 4, 2023
